BRPI0915204A2 - derivados de azacarbolinas, a respectiva preparação e sua utilização terapêutica - Google Patents

derivados de azacarbolinas, a respectiva preparação e sua utilização terapêutica

Info

Publication number
BRPI0915204A2
BRPI0915204A2 BRPI0915204A BRPI0915204A BRPI0915204A2 BR PI0915204 A2 BRPI0915204 A2 BR PI0915204A2 BR PI0915204 A BRPI0915204 A BR PI0915204A BR PI0915204 A BRPI0915204 A BR PI0915204A BR PI0915204 A2 BRPI0915204 A2 BR PI0915204A2
Authority
BR
Brazil
Prior art keywords
optionally substituted
therapeutic use
branched
heterocycloalkyl
azacarbolines
Prior art date
Application number
BRPI0915204A
Other languages
English (en)
Inventor
Arendt Christopher
Papin David
Babin Didier
Levit Mikhail
Moorcroft Neil
Bedel Olivier
Li Ronghua
Mignani Serge
Gouyon Thierry
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0915204A2 publication Critical patent/BRPI0915204A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

derivados de azacarbolinas, a respectiva preparação e sua utilização terapêutica a presente invenção refere-se a novas azacarbolinas de fórmula (1), na qual r3, r4 representam, independentemente um do outro, h; hal; cf3; óxi substituído; alcóxi eventualmente substituído; amino eventualmente substituído; carbonila substituída; carboxila eventualmente substituída, amida eventualmente substituída; enxofre, tais como os sulfetos, sulfóxidos ou sulfonas eventualmente substituídos; c1-c10 alquila linear, ramificada ou cíclica, comportando eventualmente um heteroátomo eventualmente substituído; c2-c7 alquenila, linear, ramificada ou cíclica eventualmente substituída; c2-c6 alquinila, linear ou ramificada eventualmente substituída; arila ou heteroarila, eventualmente substituída; heterocicloalquila eventualmente substituída; r6 representa heteroarila, c(o)nr1ar1b, heterocicloalquila ou -c(o)heterocicloalquila, todos eventualmente substituídos; no estado de base ou de sal de adição de ácido. utilização em terapêutica para o tratamento do câncer e processos de síntese.
BRPI0915204A 2008-06-12 2009-06-11 derivados de azacarbolinas, a respectiva preparação e sua utilização terapêutica BRPI0915204A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0803262 2008-06-12
PCT/FR2009/051100 WO2009150381A2 (fr) 2008-06-12 2009-06-11 Derives d'azacarbolines, leur preparation et leur utilisation therapeutique

Publications (1)

Publication Number Publication Date
BRPI0915204A2 true BRPI0915204A2 (pt) 2019-01-15

Family

ID=40445526

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915204A BRPI0915204A2 (pt) 2008-06-12 2009-06-11 derivados de azacarbolinas, a respectiva preparação e sua utilização terapêutica

Country Status (26)

Country Link
US (1) US20110178053A1 (pt)
EP (1) EP2303882A2 (pt)
JP (1) JP2011522867A (pt)
KR (1) KR20110016998A (pt)
CN (1) CN102124007A (pt)
AR (1) AR072084A1 (pt)
AU (1) AU2009259114B2 (pt)
BR (1) BRPI0915204A2 (pt)
CA (1) CA2725093A1 (pt)
CO (1) CO6280536A2 (pt)
CR (1) CR11814A (pt)
DO (1) DOP2010000366A (pt)
EA (1) EA018945B1 (pt)
EC (1) ECSP10010670A (pt)
IL (1) IL209840A0 (pt)
MA (1) MA32460B1 (pt)
MX (1) MX2010013699A (pt)
NI (1) NI201000210A (pt)
NZ (1) NZ589839A (pt)
PE (1) PE20110122A1 (pt)
SV (1) SV2010003754A (pt)
TW (1) TW201002711A (pt)
UA (1) UA101668C2 (pt)
UY (1) UY31895A (pt)
WO (1) WO2009150381A2 (pt)
ZA (1) ZA201008387B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072092A1 (es) * 2008-06-11 2010-08-04 Genentech Inc Diazacarbazoles y metodos de uso
PE20110061A1 (es) 2008-06-12 2011-01-31 Janssen Pharmaceutica Nv Derivados de diamino-piridina, pirimidina y piridazina como moduladores del receptor h4 de histamina
UY32275A (es) * 2009-03-24 2010-06-30 Sanofi Aventis DERIVADOS DE AZACARBOLINAS 9H-PIRROLO[2,3-b:5,4-c'] DIPIRIDINA, SU PREPARACION Y SU UTILIZACIÓN TERAPÉUTICA.
FR2950891B1 (fr) * 2009-10-06 2012-11-09 Sanofi Aventis Derives d'azacarbolines 9h-pyrrolo[2,3-b:5,4-c']dipyridine, leur preparation et leur utilisation therapeutique
FR2953838B1 (fr) * 2009-12-10 2012-02-24 Sanofi Aventis Derives de 9h-beta-carboline (ou 9h-pyridino[3,4-b]indole) trisubstitues, leur preparation et leur utilisation therapeutique
US20110183938A1 (en) * 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
JP6401773B2 (ja) * 2013-03-11 2018-10-10 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法
KR101612179B1 (ko) * 2013-04-19 2016-04-12 영남대학교 산학협력단 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물
CN103408573B (zh) * 2013-07-12 2015-12-23 上海工程技术大学 硼酸衍生物及其制备方法和应用
CN110198941B (zh) * 2017-01-25 2021-09-28 江苏豪森药业集团有限公司 吡咯并吡啶类n-氧化衍生物及其制备方法和应用
JP7365332B2 (ja) * 2017-08-07 2023-10-19 ジョイント・ストック・カンパニー “バイオキャド” Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物
ES3061844T3 (en) 2018-05-04 2026-04-07 Incyte Corp Salts of an fgfr inhibitor
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
CN116693449A (zh) 2022-03-04 2023-09-05 上海致根医药科技有限公司 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
AR072092A1 (es) * 2008-06-11 2010-08-04 Genentech Inc Diazacarbazoles y metodos de uso

Also Published As

Publication number Publication date
AU2009259114A1 (en) 2009-12-17
CN102124007A (zh) 2011-07-13
EA018945B1 (ru) 2013-11-29
MX2010013699A (es) 2011-02-23
WO2009150381A3 (fr) 2010-02-18
CR11814A (es) 2011-01-10
ECSP10010670A (es) 2011-01-31
MA32460B1 (fr) 2011-07-03
CO6280536A2 (es) 2011-05-20
TW201002711A (en) 2010-01-16
CA2725093A1 (fr) 2009-12-17
DOP2010000366A (es) 2010-12-31
US20110178053A1 (en) 2011-07-21
WO2009150381A2 (fr) 2009-12-17
SV2010003754A (es) 2011-03-15
UA101668C2 (ru) 2013-04-25
AR072084A1 (es) 2010-08-04
EA201170002A1 (ru) 2011-08-30
NI201000210A (es) 2011-05-09
EP2303882A2 (fr) 2011-04-06
NZ589839A (en) 2012-07-27
PE20110122A1 (es) 2011-03-07
KR20110016998A (ko) 2011-02-18
JP2011522867A (ja) 2011-08-04
ZA201008387B (en) 2012-02-29
UY31895A (es) 2010-01-29
IL209840A0 (en) 2011-02-28
AU2009259114B2 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
DOP2010000366A (es) Derivados de azacarbolinas, su preparacion y su utilizacion terapeutica
EA201400258A1 (ru) Модуляторы tgr5 и способы их применения
BR112012014180A2 (pt) composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio.
BR112012033402A2 (pt) moduladores de canais de íons conforme os compostos heterocíclicos fundidos
EP2968335A4 (en) SYNTHESIS AND COMPOSITION OF COMPOUNDS USED TO TARGET TUMOR FORMING OF CONJUGATED AMINO ACID COMPOUNDS
EA201170705A1 (ru) Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1
CY1112298T1 (el) Ενωσεις και μεθοδοι για ρυθμιση fxr
BRPI0510666A (pt) compostos de amida de arila ou heteroarila de metila substituìda, composições farmacêuticas compreendendo os mesmos, uso e combinação
BR112012003464B8 (pt) compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica
ATE540037T1 (de) Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten
BRPI1009637A2 (pt) composto, composição e uso de um composto
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
UY31065A1 (es) Heterociclos ciclicos
GT200800189A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
EA200970428A1 (ru) [f-18]-меченая l-глутаминовая кислота, [f-18]-меченый l-глутамин, их производные и их применение, а также способ их получения
EA201071019A1 (ru) Кристаллические формы производных фениламинопиримидина
BR112015006737A2 (pt) compostos de sulfonamida substituídos
BR112014029972A2 (pt) reagentes de conjugação
PT2323972E (pt) Compostos de tetraciclina substituídos com c7-flúor
BRPI0508047A (pt) derivados de alquilpiperazina-e alquil-homopiperazina-carboxilatos, o respectivo preparo e a respectiva aplicação como inibidores da enzima faah
EA201071238A1 (ru) Замещённое карбинольное соединение, содержащее циклический линкер
EA201001766A1 (ru) Новые[f-18]-меченые производные l-глутаминовой кислоты и l-глутамина (i), их применение, а также способ их получения
BRPI0510940A (pt) 1-aza-biciclo-3.1.1-nonanos
BR112013029730A2 (pt) composição farmacêutica de rosuvastatina cálcica
ATE555116T1 (de) Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2507 DE 22-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]